"$4B per year" AE cost to UK health service

13 April 2008

The cost to the UK's National Health Service of prescription drug-related adverse events is nearly L2.0 billion ($3.99 billion), according to a report in the left-leaning Guardian newspaper. The figure was produced by what the Guardian described as a "center-left think-tank," Compass. Unusually, the claim was made concerning research which the group announced it will publish in the fall.

However, Compass has been described as more of a caucus within the governing UK Labour Party than a research center and the group admitted it had calculated the total of almost L1.90 billion spent on medicine-related adverse events, on the basis of an estimated 6.5% of NHS hospital admissions and combined it with the average daily cost of an eight-day hospital stay.

The author of the Compass' report, Zoe Gannon, said that the cost of treating patients with adverse events "could pay for 10,000 new midwives and could easily cover the estimated cost of combating MRSA [methicillin-resistant Staphylococcus aureus] infections.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight